Kathryn E Wengel Net Worth

Track Major Insider Updates On X/Twitter

Last Updated: 20 hours ago

Kathryn E Wengel has an estimated net worth of at least $45.5 million*, as of yesterday. They own 124,287 shares of JNJ stock. They have sold 78,875 shares of JNJ stock since 2021, for an estimated $14.2 million.

Kathryn E Wengel $JNJ SEC Form 4 Insider Trading

Kathryn E Wengel has filed a total of 7 insider trades in $JNJ since 2021. Their most recent trade was a sale of 10,000 shares, made on Jun 11, 2026. Their largest trade was a sale of 33,126 shares, made on Jun 10, 2022. We estimate that they now own 124,287 shares of $JNJ, worth an estimated $31.3 million.

Insider Trading at $JNJ

There have been a total of 374 insider trades reported at $JNJ since 2021, with 2,250 shares purchased and 1.2 million shares sold. The most active insider traders in $JNJ stock have been Peter Fasolo, Thibaut Mongon, and William Hait. The most recent trade was a sale of 10,000 shares reported by Kathryn E Wengel (EVP, Chief TO and Risk Officer), made on Jun 11, 2026.

History of Insider Stock Trades by Kathryn E Wengel

Company Ticker	Purchase / Sale	Shares	Date	Disclosed (EST)
JNJ	Sale	10,000	Jun 11, 2026	June 12, 2026, 5:23 p.m.
JNJ	Sale	12,465	Jun 12, 2023	June 14, 2023, 4:19 p.m.
JNJ	Sale	16,410	Nov 09, 2022	Nov. 10, 2022, 5:47 p.m.
JNJ	Sale	100	Jun 10, 2022	June 14, 2022, 6:28 p.m.
JNJ	Sale	33,126	Jun 10, 2022	June 14, 2022, 6:28 p.m.
JNJ	Sale	174	Jun 10, 2022	June 14, 2022, 6:28 p.m.
JNJ	Sale	6,600	Jun 10, 2022	June 14, 2022, 6:28 p.m.

$JNJ Executives and Stock Owners with Insider Trades

Peter Fasolo, Exec VP, Chief HR Officer
Thibaut Mongon, Exec VP, WW Chair, Consumer
William Hait, See Remarks
Joseph J Wolk, Exec VP, CFO
John C Reed, EVP, Innovative Medicine, R&D
Kathryn E Wengel, EVP, Chief GSC Officer
Timothy Schmid, EVP, WW Chair, MedTech
Joaquin Duato, CEO and Chairman of the Board
Robert J Decker, Controller, CAO
Robert J Decker, VP Corporate Controller
James D. Swanson, EVP, CIO
Jennifer L Taubert, EVP, WW Chair, Pharmaceuticals
Kathryn E Wengel, EVP, Chief TO and Risk Officer
Vanessa Broadhurst, EVP, Global Corp Affairs
Ashley Mcevoy, EVP, WW Chair, MedTech
Jennifer L Taubert, EVP, WWC. Innovative Medicine
James D. Swanson, See Remarks

*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.